Multiple sclerosis dating sites uk
Daclizumab (Zinbryta▼) 150 mg solution for injection was authorised in the EU in July 2016 for adults with relapsing forms of multiple sclerosis.
Important Cookie Information - this message will appear only once.
Closely watch patients for signs and symptoms of hepatic injury.
If there is evidence of hepatic injury (either clinically or laboratory), treatment should be stopped and the patient should be promptly referred to a hepatologist.
The European Medicines Agency (EMA) has now restricted the use of daclizumab to patients whose disease has responded inadequately to at least 2 disease modifying therapies (DMTs) and cannot be treated with any other DMTs (see the EMA website for further details).
This means that part of the population in whom daclizumab is currently recommended in NICE technology appraisal guidance 441 is outside the revised licensed indication of the drug.
These pages provide information about services, events and research at the Queen Elizabeth Hospital for patients with multiple sclerosis (MS).